ClinicalTrials.gov
public full text
Public Domain
PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT
All patients received Flu-BU-VP16 as myeloablative conditioning followed by cyclophosphamide (D+3 and +4) and subsequent tacrolimus. For patients with unrelated or haplo-donor received low-dose ATG at Day +15.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT#866851
- Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT#890604
- Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation#981393
- Palifermin After Haploidentical PBSCT#864654
- Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia#1139560
Record · ID 1093512
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive